LUCD Valuation
Lucid Diagnostics Inc
$
1.300
- Overview
- Forecast
- Valuation
LUCD Relative Valuation
LUCD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LUCD is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for LUCD's competitors is 13.45, providing a benchmark for relative valuation. Lucid Diagnostics Inc Corp (LUCD) exhibits a P/S ratio of 15.56, which is 15.68% above the industry average. Given its robust revenue growth of -17.28%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
TSLA
Tesla Inc
343.820
USD
+0.51%
AAPL
Apple Inc
206.860
USD
-0.92%
META
Meta Platforms Inc
637.100
USD
-0.52%
AVGO
Broadcom Inc
231.680
USD
+0.46%
MSFT
Microsoft Corp
458.170
USD
-0.15%
ORCL
Oracle Corp
160.310
USD
+0.42%
XOM
Exxon Mobil Corp
104.950
USD
-1.43%
WMT
Walmart Inc
97.800
USD
-0.33%
AMZN
Amazon.com Inc
204.070
USD
-1.01%
NVDA
NVIDIA Corp
134.380
USD
-0.88%
FAQ
Is Lucid Diagnostics Inc (LUCD) currently overvalued or undervalued?
Lucid Diagnostics Inc (LUCD) is now in the Overvalued zone, suggesting that its current forward PS ratio of 15.56 is considered Overvalued compared with the five-year average of 27.86. The fair price of Lucid Diagnostics Inc (LUCD) is between 0.65 to 1.03 according to relative valuation methord. Compared to the current price of 1.30 USD , Lucid Diagnostics Inc is Overvalued By 25.84% .
What is Lucid Diagnostics Inc (LUCD) fair value?
How does LUCD's valuation metrics compare to the industry average?
What is the current P/B ratio for Lucid Diagnostics Inc (LUCD) as of May 21 2025?
What is the current FCF Yield for Lucid Diagnostics Inc (LUCD) as of May 21 2025?
What is the current Forward P/E ratio for Lucid Diagnostics Inc (LUCD) as of May 21 2025?